Billion-dollar deal propels RNAi to CNS frontier

Biotech giant Regeneron partners with Alnylam to expand RNAi therapies beyond the liver and into the brain.
Dublin, Ireland

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

doi: 10.1038/d41587-019-00014-7
Nature Briefing

Sign up for the daily Nature Briefing email newsletter

Stay up to date with what matters in science and why, handpicked from Nature and other publications worldwide.

Sign Up